Silence Therapeutics (SLN) Liabilities and Shareholders Equity (2018 - 2026)

Silence Therapeutics has disclosed Liabilities and Shareholders Equity across 9 years of filings, most recently posting $115.1 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $115.1 million, down 37.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $558.6 million (up 43.99% YoY), and the FY2025 annual result was $131.4 million, down 35.13% from the prior year.
• Liabilities and Shareholders Equity came in at $115.1 million for Q1 2026 at Silence Therapeutics, down from $131.4 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $202.6 million in Q4 2024 to a low of $115.1 million in Q1 2026.
• The 5-year median for Liabilities and Shareholders Equity is $139.1 million (2025), against an average of $149.0 million.
• Across the five-year window, Liabilities and Shareholders Equity surged 69.64% in 2024 and sank 37.87% in 2026, its largest moves.
• Silence Therapeutics' Liabilities and Shareholders Equity stood at $126.1 million in 2022, then dropped by 5.27% to $119.4 million in 2023, then soared by 69.64% to $202.6 million in 2024, then tumbled by 35.13% to $131.4 million in 2025, then decreased by 12.42% to $115.1 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $115.1 million (Q1 2026), $131.4 million (Q4 2025), and $146.8 million (Q3 2025), per Business Quant data.